Every 8-K that Inovio Pharmaceu (INO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow INO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full INO filings page.
Inovio Pharmaceuticals reported second-quarter 2026 results with no revenue and a net loss of $6.0 million, or $0.07 per share, compared with a net loss of $23.5 million a year earlier. The narrower loss was largely driven by a $13.9 million non-cash gain from revaluing common stock warrant liabilities, which can cause significant volatility in reported earnings.
Research and development expenses fell to $10.8 million and general and administrative expenses to $7.8 million, bringing total operating expenses to $18.6 million. Cash, cash equivalents and short-term investments were $36.7 million as of June 30, 2026, plus net proceeds of about $18.3 million from a July equity offering, and the company estimates this will fund operations into late first quarter 2027.
Regulatory progress continued for lead candidate INO-3107 for recurrent respiratory papillomatosis, with FDA review of the Biologics License Application underway and a PDUFA target date of October 30, 2026. Inovio is preparing for a potential U.S. launch, having engaged Syneos Health and other commercial partners. Partner ApolloBio reported positive Phase 3 topline results in China for VGX-3100 in cervical dysplasia, and Inovio highlighted promising preclinical data from its DNA-Encoded Monoclonal Antibody and DNA-Encoded Protein platforms.
Inovio Pharmaceuticals, Inc. entered into an underwriting agreement with Piper Sandler for a public offering of 21,052,632 shares of common stock and accompanying warrants to purchase up to 42,105,264 shares of common stock, at a combined public offering price of $0.95 per share of common stock and accompanying warrant.
Each warrant is immediately exercisable for two shares at an exercise price of $1.10 per share (or $1.099 per pre-funded warrant) and will expire five years from issuance, subject to beneficial ownership limits of 4.99%, 9.99% or 19.99% as elected by the holder. The underwriter has a 30‑day option to purchase up to 3,157,894 additional shares and/or warrants to purchase up to 6,315,788 shares and has exercised this option with respect to the additional warrants.
Gross proceeds are expected to be approximately $20.0 million before underwriting discounts and commissions and offering expenses, excluding any exercise of the underwriter’s option to purchase additional securities and assuming no exercise of the accompanying warrants. Net proceeds to Inovio are expected to be about $18.3 million after such costs, including the underwriter’s purchase of additional warrants and assuming no exercise of its option to purchase additional shares, with closing expected on or about July 31, 2026, subject to customary conditions.
Inovio Pharmaceuticals, Inc. provides a preliminary estimate of its liquidity, stating that as of June 30, 2026 it had approximately $36.7 million in cash and cash equivalents. This figure is based on management estimates and has not yet gone through full quarter-end closing procedures.
The estimate is described as preliminary unaudited information and may change once financial closing activities and reviews of internal controls are completed. The company notes that its independent registered public accounting firm, Ernst & Young LLP, has not audited, reviewed, examined, or compiled this data, and gives cautionary language about forward-looking statements and potential differences from final results.
Inovio Pharmaceuticals, Inc. reported governance changes and voting results from its 2026 annual stockholder meeting. On May 19, 2026, the board approved a bylaws amendment clarifying that the Chairman of the Board is not an officer unless specifically designated, formally creating a Lead Independent Director role when the Chief Executive Officer also serves as Chairman, and updating the order of presiding officers at board and stockholder meetings.
On May 20, 2026, stockholders holding 40,670,629 shares, or 58.57% of the 69,438,100 shares entitled to vote, were present or represented by proxy. All eight director nominees were elected. Stockholders ratified Ernst & Young LLP as independent auditor for the fiscal year ending December 31, 2026, approved on a non-binding basis the compensation of named executive officers, and approved amendments to the Amended and Restated 2023 Omnibus Incentive Plan.
INOVIO Pharmaceuticals reported a first-quarter 2026 net loss of $19.7 million, or $0.28 per share, roughly in line with the prior year. Operating expenses fell to $21.9 million from $25.1 million as both R&D and G&A spending decreased.
The company ended March 31, 2026 with $37.7 million in cash, cash equivalents and short-term investments, before adding $16.0 million of net equity offering proceeds in April. Management expects this liquidity to fund operations into the first quarter of 2027, beyond the FDA’s target October 30, 2026 PDUFA date for lead candidate INO-3107.
The Biologics License Application for INO-3107 in recurrent respiratory papillomatosis is under active FDA review in the accelerated approval program, following completion of the mid-cycle review. INOVIO is preparing for a potential 2026 U.S. commercial launch and pursuing partnerships on other pipeline assets, including a GBM collaboration with Akeso for INO-5412.
Inovio Pharmaceuticals entered an underwriting agreement for an underwritten public offering of 12,500,000 shares of common stock, together with Series A and Series B warrants, at a combined public offering price of $1.40 per share and accompanying warrants.
The gross proceeds are expected to be approximately $17.5 million, with net proceeds to Inovio of about $16 million after underwriting discounts and expenses, assuming no exercise of the underwriters’ option or the warrants. All securities in the deal are being sold by the company.
Each Series A and Series B warrant allows purchase of one share at an exercise price of $1.40 per share (or $1.399 per pre-funded warrant), with the Series A warrants expiring one year from issuance and Series B warrants expiring five years from issuance. The underwriters have a 30‑day option to buy up to 1,875,000 additional shares and corresponding warrants. Warrant exercises are subject to a beneficial ownership cap of 4.99% or, at the holder’s election, 9.99% of outstanding common stock.
Inovio Pharmaceuticals, Inc. filed an update stating it has suspended and terminated the August 13, 2024 prospectus for its at-the-market stock offering program with Oppenheimer & Co. Inc. While the underlying sales agreement remains in effect, the company will not sell additional common stock under this program unless and until a new prospectus is filed. As of April 1, 2026, Inovio had issued 1,319,644 shares of common stock through this at-the-market program for aggregate gross proceeds of $3.2 million, before sales commissions and offering expenses.
INOVIO reported 2025 results alongside a major regulatory milestone for its lead DNA medicine INO-3107. The FDA accepted the Biologics License Application for recurrent respiratory papillomatosis under the accelerated approval program, with a PDUFA target date of October 30, 2026, while noting questions about accelerated approval eligibility that will be discussed at a future meeting.
The company advanced commercial readiness for INO-3107 and expanded its oncology and next‑generation DNA medicine pipeline, including a GBM collaboration with Akeso and published DMAb and DPROT data. INOVIO emphasized cost discipline, prioritizing INO-3107 and trimming roles not directly supporting this program.
Financially, 2025 research and development expenses fell to $54.2 million from $75.6 million, and general and administrative expenses declined to $32.7 million from $37.0 million, reducing total operating expenses to $86.9 million from $112.6 million. Net loss for 2025 narrowed to $84.9 million, or $1.81 per share, versus $107.3 million, or $3.95 per share in 2024; fourth‑quarter 2025 showed net income of $3.8 million, mainly from a $21.2 million non‑cash gain on warrant liabilities.
Cash, cash equivalents and short‑term investments were $58.5 million as of December 31, 2025, down from $94.1 million a year earlier, with 68,996,647 common shares outstanding. Management expects existing liquidity to fund operations into the fourth quarter of 2026, assuming an estimated operational net cash burn of about $22 million for the first quarter of 2026.
Inovio Pharmaceuticals, Inc. has amended its outstanding Series A warrants to extend their expiration. The warrants, originally set to expire on January 28, 2026, will now be exercisable until 5:00 p.m. New York City time on March 31, 2026. These Series A warrants were issued in Inovio’s July 2025 underwritten public offering and are exercisable for up to 13,564,268 shares of common stock, or pre-funded warrants in lieu of common stock. The exercise price is $1.75 per share of common stock, or $1.749 per pre-funded warrant. All other terms of the Series A warrants remain unchanged.
Inovio Pharmaceuticals entered an underwriting agreement for a public offering of 13,158,000 shares of common stock at $1.90 per share. The underwriters exercised in full their 30‑day option to buy up to 1,973,700 additional shares on the same terms. All shares are being sold by the company.
Including the option shares, net proceeds to Inovio are expected to be approximately $26.5 million after underwriting discounts and estimated expenses. The closing is expected on or about November 12, 2025, subject to customary conditions. The transaction is being conducted under an effective Form S‑3 shelf, supplemented by a prospectus filed pursuant to Rule 424(b).
Inovio Pharmaceuticals (INO) filed an 8-K stating it furnished a press release announcing financial results for the quarter ended September 30, 2025. The release is attached as Exhibit 99.1.
Per Item 2.02 and General Instruction B.2, this information is being furnished and is not deemed filed under the Exchange Act. The report is dated November 10, 2025 and was signed by CFO Peter Kies.
Inovio Pharmaceuticals, Inc. filed a current report to share that it issued a press release with its financial results for the quarter ended June 30, 2025. The press release, dated August 12, 2025, is attached as Exhibit 99.1 and incorporated by reference.
The company is using this report under Item 2.02, which covers results of operations and financial condition. The information in Item 2.02 and Exhibit 99.1 is being furnished, rather than filed, meaning it is not subject to certain liability provisions of the Exchange Act or automatically incorporated into other Securities Act or Exchange Act filings unless specifically referenced.